conducted target trial emulations comparing dual GLP-1/GIP agonists to GLP-1 monotherapy in patients with type 2 diabetes, finding that dual agonists were linked to numerically lower risks of MALOs, although confidence intervals overlapped, suggesting that extended observation period and larger patient cohorts may be needed to definitively establish comparative effectiveness [61]
Given the established cardiovascular and kidney benefits of SGLT2is for T2DM patients with CVDs, those at high risk, and those with CKD, along with recent cohort studies demonstrating their ability to enhance survival, reduce cardiovascular events, and preserve graft function in kidney KTRs with DM, we conducted additional analyses incorporating SGLT2is [38,39,40,41,42]
Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial
Use our peptide calculator to help track your dosing and supplementation alongside medication dosing